SWTX News and Press, SpringWorks Therapeutics Inc. From 01/22/24

2024-01-22 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42 nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET), ...

2023-12-27 15:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthc...

2023-12-08 16:10:03 ET More on SpringWorks Therapeutics SpringWorks: Springing Forward On FDA Approval, Right Into Overpriced Territory SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear SpringWorks Therapeutics: How A Likely FDA...

STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of i...

2023-12-05 12:00:00 ET Summary In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top in...

2023-12-05 08:28:55 ET Losers: Replimune Group ( REPL ) -50% presents new data from IGNYTE clinical trial of RP1 in Anti-PD1 failed Melanoma and non-Melanoma skin cancers. iBio ( IBIO ) -38% announces pricing of $4.5 Million public offering . Designer B...

2023-12-05 06:04:31 ET More on SpringWorks Therapeutics SpringWorks: Springing Forward On FDA Approval, Right Into Overpriced Territory SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear SpringWorks Therapeutics: How A Likely FDA...